Tagged with Reimbursement

healthcare Nefarma’s healthcare policy advisor discusses the changes in the Dutch reimbursement system over the previous five years, and the need for greater trust between different healthcare stakeholders to allow effective collaboration and negotiation. How has the pharmaceutical reimbursement system in the Netherlands changed over the last few years? To start…

Chiesi Chiesi is preparing to market two first in class products: the first approved stem cell treatment in Europe, and the first approved gene-therapy, developed in the Netherlands by partner UniQure. General Manager Nether Maurits Huigen discusses the challenges his affiliate is facing to bringing these pioneering products to market, along…

insurance Jim O’Drobinak came to Puerto Rico at the end of 2011, following a career largely based in Florida, to run Medical Card System (MCS), a major insurance provider on the island. He shares his experiences and challenges to ensure a functioning health system in a time of doubt regarding healthcare…

reimbursement The country manager of a JNJ affiliated company advocates deploying electronic healthcare techniques to transform the reach of local practitioners and speaks out about the sort of local adaptations that need to be considered when introducing new products to the Algerian market. What is your evaluation of the Algerian pharmaceutical…

government The national coordinator for Argentina’s ministry of health Plan Remediar discusses developing a professional management culture in the country’s public health centers, and the programs wider role in the public health system.   Would you begin by giving our readers a brief introduction to Plan Remediar, and the scope of…

Frost & Sullivan Rhenu Bhuller provides insight into Malaysia’s healthcare industry positioning in the Southeast Asian region and the ability to provide affordable quality healthcare in a country that is naturally diverse as an important competitive advantage.   The pharmaceutical sector has been the fastest growing industry in Malaysia between 2000 and 2009,…

Biosano “A company active in the Chilean pharmaceutical market has to reinvent its business model every three years because today we are competing against some of the largest multinationals.”     How has the company developed over the past years? Chile has a very open and transparent market, which requires companies to…

Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…

Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…

Generics The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the positive and negative aspects of the new legislative framework implemented in January 2012? The positive aspects of the Reimbursement Act…

chronic pain Bene Farmacêutica was established in 2009 to expand the supply and presence of Bene-Arzneimittel in Portugal, having already sold products in the country for several decades. The affiliate’s managing director, Frank Tischler, outlines Bene Farmacêutica’s entrance into Portugal and discusses the importance of adding value to brands in an environment…

Infarmed Eurico Castro Alves, president of Portugal’s regulatory agency Infarmed, talks about the biggest challenges facing the regulation of health products in the country today, and introduces new initiatives aimed at positioning Infarmed as a regulator of reference worldwide.   You have been president of Infarmed since 2012. What have been some…